We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Efficacy Study of Tarceva, Temodar, and Radiation Therapy in Patients With Newly Diagnosed Brain Tumors

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00187486
First Posted: September 16, 2005
Last Update Posted: September 4, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Genentech, Inc.
Information provided by (Responsible Party):
University of California, San Francisco
Results First Submitted: April 25, 2011  
Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment;   Masking: None (Open Label);   Primary Purpose: Treatment
Conditions: Glioblastoma Multiforme
Gliosarcoma
Interventions: Drug: Tarceva
Drug: Temodar
Procedure: Radiation Therapy

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
66 patients enrolled from 10/2004 - 2/2006. Patients were enrolled at the UCSF Neuro-Oncology clinic.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Temodar Plus Tarceva Plus Radiotherapy All patients were treated with radiotherapy and temozolomide; patients were treated with dosing of tarceva based upon use of enzyme-inducing antiepileptic drugs

Participant Flow:   Overall Study
    Temodar Plus Tarceva Plus Radiotherapy
STARTED   66 
COMPLETED   65 
NOT COMPLETED   1 
Protocol Violation                1 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Temodar Plus Tarceva Plus Radiotherapy All patients were treated with radiotherapy and temozolomide; patients were treated with dosing of tarceva based upon use of enzyme-inducing antiepileptic drugs

Baseline Measures
   Temodar Plus Tarceva Plus Radiotherapy 
Overall Participants Analyzed 
[Units: Participants]
 66 
Age 
[Units: Participants]
Count of Participants
 
<=18 years      0   0.0% 
Between 18 and 65 years      55  83.3% 
>=65 years      11  16.7% 
Age 
[Units: Years]
Mean (Standard Deviation)
 54  (11) 
Sex: Female, Male 
[Units: Participants]
Count of Participants
 
Female      24  36.4% 
Male      42  63.6% 
Region of Enrollment 
[Units: Participants]
 
United States   66 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Overall Survival   [ Time Frame: assessment of survival was every 2 months, up to 181 weeks ]

2.  Secondary:   Progression Free Survival   [ Time Frame: every 2 months measure by MR imaging, up to 39 months ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Results Point of Contact:  
Name/Title: Michael Prados, MD
Organization: University of California San Francisco
phone: 415 353 2076
e-mail: PradosM@neurosurg.ucsf.edu


Publications of Results:

Responsible Party: University of California, San Francisco
ClinicalTrials.gov Identifier: NCT00187486     History of Changes
Other Study ID Numbers: CC 04101
OSI 2725s ( Other Identifier: Genentech, Inc )
First Submitted: September 13, 2005
First Posted: September 16, 2005
Results First Submitted: April 25, 2011
Results First Posted: September 27, 2012
Last Update Posted: September 4, 2017